A Multicenter Phase II Study of Adjuvant Chemotherapy With Oral Fluoropyrimidine S-1 for Non-Small-Cell Lung Cancer: High Completion and Survival Rates

摘要

As oral chemotherapy might reduce physiological and psychological burdens on patients, we conducted a feasibility study using S-1, an oral fluoropyrimidine, as postoperative chemotherapy in 50 patients with curatively resected stage IB-IIIA non-small-cell lung cancer. The completion rate was 72.0% and the 3-year relapse-free survival rate was 69.4%. This protocol seems feasible and may be sufficient to prevent recurrence.